Brief: Aerovate Therapeutics Presents Baseline Data From The Phase 2B Portion Of The Impahct Trial
21/05/2024 21:47
May 21 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS PRESENTS BASELINE DATA FROM THE
PHASE 2B
PORTION OF THE IMPAHCT TRIAL AT THE AMERICAN THORACIC SOCIETY
2024 INTERNATIONAL CONFERENCE
* TOPLINE DATA FROM PHASE 2B PORTION OF IMPAHCT STUDY TO BE
RELEASED IN JUNE 2024
Source text for Eikon: ID:nGNX53wtNd
Further company coverage: AVTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million